RxDoctor Payments Data

Nima Ghadimi, MD

Internal Medicine · Scottsdale, AZNPI 1891894333

Payments from drug & device makers

$461in general payments, 2019–2025

Across 19 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$175
  • Teva Pharmaceuticals USA, Inc.$125
  • Exact Sciences$52
  • Astellas Pharma US Inc$24
  • Tolmar, Inc.$21
  • Boehringer Ingelheim$17
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$461 in reported general payments places this provider in the 65th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$49,038
Medicare patients
66
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$32,064
JardianceEmpagliflozin34$30,346
OzempicSemaglutide25$29,376
MounjaroTirzepatide20$20,061
TrulicityDulaglutide11$14,876
JanuviaSitagliptin Phosphate12$11,113
Omega-3 Acid Ethyl Esters34$3,867
Hydromorphone Hcl22$2,655
Morphine Sulfate ErMorphine Sulfate22$2,539
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,493
Morphine Sulfate17$1,809
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$1,529
Duloxetine Hcl40$1,507
Gabapentin74$1,277
Oxycodone Hcl64$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$32,06452 claims
Boehringer IngelheimJardiance$17$30,34634 claims
Novo NordiskOzempic$175$29,37625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →